{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:25:44Z","timestamp":1784903144715,"version":"3.55.0"},"reference-count":21,"publisher":"The Endocrine Society","issue":"11","funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK069350"],"award-info":[{"award-number":["R01DK069350"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Context<\/jats:title>\n                  <jats:p>Conventional treatment of hypoparathyroidism is associated with decreased renal function and increased bone mineral density (BMD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the effects of 8 years of recombinant human parathyroid hormone (1-84) [rhPTH(1-84)] therapy on key biochemical and densitometric indices.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Prospective open-label trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>Tertiary medical center.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Twenty-four subjects with hypoparathyroidism.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>Treatment with rhPTH(1-84) for 8 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Supplemental calcium and vitamin D requirements, serum calcium and phosphorus levels, calcium-phosphate product, urinary calcium excretion, estimated glomerular filtration rate (eGFR) and BMD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>PTH therapy was associated with progressive reduction in supplemental calcium (57%; P &lt; 0.01) and active vitamin D (76%; P &lt; 0.001) requirements over 8 years. Serum calcium concentration was stable; urinary calcium excretion declined 38% (P &lt; 0.01). eGFR remained stable and was related to baseline eGFR and serum calcium levels. Calcium-phosphate product was below the recommended limit; serum phosphorus remained within normal range. Lumbar spine and total hip BMD increased, peaking at 4 (mean \u00b1 SE, 4.6% \u00b1 1.5%; P = 0.01) and 8 years (2.6% \u00b1 1.1%; P = 0.02), whereas femoral neck BMD did not change and one-third radius BMD decreased (mean \u00b1 SE, \u22123.5% \u00b1 1.1%; P = 0.001). BMD at all sites was higher throughout the 8 years than in the age- and sex-matched reference population. Hypercalcemia and hypocalcemia were uncommon.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>rhPTH(1-84) is a safe and effective treatment for hypoparathyroidism for 8 years. Long-term reductions in supplemental requirements and biochemical improvements with stable renal function are maintained.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/jc.2019-00893","type":"journal-article","created":{"date-parts":[[2019,7,16]],"date-time":"2019-07-16T09:06:18Z","timestamp":1563267978000},"page":"5601-5610","source":"Crossref","is-referenced-by-count":72,"title":["Therapy of Hypoparathyroidism With rhPTH(1-84): A Prospective, 8-Year Investigation of Efficacy and Safety"],"prefix":"10.1210","volume":"104","author":[{"given":"Yu-Kwang Donovan","family":"Tay","sequence":"first","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York"},{"name":"Department of Medicine, Sengkang General Hospital, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Tabacco","sequence":"additional","affiliation":[{"name":"Unit of Endocrinology and Diabetes, Department of Medicine, University Campus Bio-Medico, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie E","family":"Cusano","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology Lenox Hill Hospital, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Williams","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Omeragic","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rukshana","family":"Majeed","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximo","family":"Gomez Almonte","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Cardiology, Wyckoff Heights Medical Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P","family":"Bilezikian","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7818-2121","authenticated-orcid":false,"given":"Mishaela R","family":"Rubin","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Endocrinology, College of Physicians and Surgeons, Columbia University, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,7,16]]},"reference":[{"issue":"11","key":"2019101003032784700_bib1","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1002\/jbmr.452","article-title":"PTH(1-84) administration reverses abnormal bone-remodeling dynamics and structure in hypoparathyroidism","volume":"26","author":"Rubin","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2019101003032784700_bib2","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1359\/jbmr.080803","article-title":"Dynamic and structural properties of the skeleton in hypoparathyroidism","volume":"23","author":"Rubin","year":"2008","journal-title":"J Bone Miner Res"},{"issue":"4","key":"2019101003032784700_bib3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1056\/NEJMcp0803050","article-title":"Hypoparathyroidism","volume":"359","author":"Shoback","year":"2008","journal-title":"N Engl J Med"},{"issue":"10","key":"2019101003032784700_bib4","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/jbmr.483","article-title":"Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research","volume":"26","author":"Bilezikian","year":"2011","journal-title":"J Bone Miner Res"},{"issue":"12","key":"2019101003032784700_bib5","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1210\/jc.2012-1808","article-title":"Long-term follow-up of patients with hypoparathyroidism","volume":"97","author":"Mitchell","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"key":"2019101003032784700_bib6","unstructured":"US Food and Drug Administration. Drug trials snapshot: NATPARA (parathyroid hormone). Available at: www.fda.gov\/Drugs\/InformationOnDrugs\/ucm435518.htm. Accessed 13 March 2018."},{"issue":"1","key":"2019101003032784700_bib7","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1210\/jc.2012-2984","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective four-year investigation of efficacy and safety","volume":"98","author":"Cusano","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"2019101003032784700_bib8","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1210\/jc.2015-4135","article-title":"Therapy of hypoparathyroidism with PTH(1-84): a prospective six year investigation of efficacy and safety","volume":"101","author":"Rubin","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2019101003032784700_bib9","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1210\/jc.2015-3907","article-title":"Management of hypoparathyroidism: summary statement and guidelines","volume":"101","author":"Brandi","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2019101003032784700_bib10","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"11","key":"2019101003032784700_bib11","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1002\/jbmr.1979","article-title":"Cardiovascular and renal complications to postsurgical hypoparathyroidism: a Danish nationwide controlled historic follow-up study","volume":"28","author":"Underbjerg","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"9","key":"2019101003032784700_bib12","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1002\/jbmr.2501","article-title":"The epidemiology of nonsurgical hypoparathyroidism in Denmark: a nationwide case finding study","volume":"30","author":"Underbjerg","year":"2015","journal-title":"J Bone Miner Res"},{"issue":"5","key":"2019101003032784700_bib13","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/jbmr.3368","article-title":"Long-term complications in patients with hypoparathyroidism evaluated by biochemical findings: a case-control study","volume":"33","author":"Underbjerg","year":"2018","journal-title":"J Bone Miner Res"},{"key":"2019101003032784700_bib14","article-title":"Standards of care for hypoparathyroidism in adults [published online ahead of print 1 December 2018]","author":"Khan","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2019101003032784700_bib15","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-15-0628","article-title":"European Society of Endocrinology clinical guideline: treatment of chronic hypoparathyroidism in adults","volume":"173","author":"Bollerslev","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2019101003032784700_bib16","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1210\/jc.2002-021736","article-title":"Long-term treatment of hypoparathyroidism: a randomized controlled study comparing parathyroid hormone-(1-34) versus calcitriol and calcium","volume":"88","author":"Winer","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"2019101003032784700_bib17","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1001\/jama.1996.03540080053029","article-title":"Synthetic human parathyroid hormone 1-34 vs calcitriol and calcium in the treatment of hypoparathyroidism","volume":"276","author":"Winer","year":"1996","journal-title":"JAMA"},{"key":"2019101003032784700_bib18","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1002\/jbmr.1964","article-title":"PTH(1-84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment","volume":"28","author":"Sikjaer","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2019101003032784700_bib19","first-page":"1617","article-title":"Bone mineral density in patients with chronic hypoparathyroidism","volume":"76","author":"Abugassa","year":"1993","journal-title":"J Clin Endocrinol Metab"},{"key":"2019101003032784700_bib20","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/jbmr.3543","article-title":"The effects of long-term administration of rhPTH(1-84) in hypoparathyroidism by bone histomorphometry","volume":"33","author":"Rubin","year":"2018","journal-title":"J Bone Miner Res"},{"issue":"19","key":"2019101003032784700_bib21","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/jc.2019-00893\/28933924\/jc.2019-00893.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/11\/5601\/30124736\/jc.2019-00893.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/104\/11\/5601\/30124736\/jc.2019-00893.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,10]],"date-time":"2019-10-10T03:06:48Z","timestamp":1570676808000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/104\/11\/5601\/5532037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,16]]},"references-count":21,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2019-00893","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,7,16]]}}}